NCT04982848 2025-11-18Korea Post Marketing Surveillance (PMS) Study of Talzenna®PfizerNot yet recruiting600 enrolled
NCT05141708 2024-02-16Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2mPfizerCompleted33 enrolled 9 charts
NCT04987931 2024-01-22Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast CancerPfizerCompleted84 enrolled 11 charts
NCT04774406 2023-06-06Arterial Hypertension Related to PARP Inhibitors (ArteRIB)University Hospital, CaenCompleted2,336 enrolled
NCT02154490 2023-06-01Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung CancerSWOG Cancer Research NetworkCompleted1,864 enrolled 12 charts
NCT04774627 2021-09-23Pancytopenia Related to PARP Inhibitors (PancytoRIB)University Hospital, CaenCompleted200 enrolled